- PR Newswire•4 hours agoAmgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients
THOUSAND OAKS, Calif., Oct. 20, 2016 /PRNewswire/ -- Amgen (AMGN) today announced that a Phase 3 study evaluating XGEVA® (denosumab) versus zoledronic acid met the primary endpoint of non-inferiority (hazard ratio = 0.98, 95 percent CI, 0.85 - 1.14) in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma. The hazard ratio of XGEVA versus zoledronic acid for overall survival was 0.90 (95 percent CI, 0.70 - 1.16). "Bone complications like fracture, spinal cord compression and radiation or surgery to bone are devastating for multiple myeloma patients.
- Investor's Business Daily•4 hours ago
Kite's pipeline is unfolding even as investors undervalue the stock, RBC analyst Michael Yee said Thursday.
- Zacks•10 hours ago
Given the current scenario of increased political, media and public pressure on drug pricing, it makes sense to zero in on companies that are in the biosimilars business.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||160.07 x 100|
|Ask||168.00 x 100|
|Day's Range||161.00 - 163.33|
|52wk Range||139.02 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||16.53|
|Avg Vol (3m)||2,763,176|
|Dividend & Yield||4.00 (2.46%)|